SCHEMBL4516986

SCHEMBL4516986

CC(=O)N1CCN(c2ccc(NC(=O)C(=O)O)cc2)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.75
KMT2A Q03164 3/20 0.75
MEN1 O00255 2/20 0.75
NPC1 O15118 4/20 0.68
RAB9A P51151 4/20 0.68
ALDH1A1 P00352 3/20 0.63
CYP2C9 P11712 1/20 0.63
HPGD P15428 1/20 0.63
CYP2C19 P33261 1/20 0.63
NAMPT P43490 1/20 0.61
MAPK1 P28482 3/20 0.60
HSD17B10 Q99714 2/20 0.60
USP2 O75604 1/20 0.60
TP53 P04637 1/20 0.60
GFER P55789 3/20 0.59
GAA P10253 3/20 0.59
ALOX15 P16050 3/20 0.59
ALOX12 P18054 3/20 0.59
CASP6 P55212 1/20 0.58
PKM P14618 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30620451 0.86 MAPT (1.00) MAPTKMT2AMEN1NPC1RAB9A
SCHEMBL3543325 0.85 MAPT (0.71) MAPTKMT2AMEN1NPC1RAB9A
SCHEMBL13755352 0.85 MAPT (0.71) MAPTKMT2AMEN1NPC1RAB9A
Bicarbonate SCHEMBL3547040 0.82 MAPT (0.71) MAPTKMT2AMEN1NPC1RAB9A
SCHEMBL4162969 0.82 MAPT (0.75) MAPTKMT2AMEN1NPC1RAB9A
SCHEMBL13105213 0.81 MAPT (0.73) MAPTKMT2AMEN1NPC1RAB9A
SCHEMBL197637 0.81 MAPT (0.73) MAPTKMT2AMEN1NPC1RAB9A
SCHEMBL3539493 0.80 MAPT (0.63) MAPTKMT2AMEN1NPC1RAB9A
SCHEMBL27022350 0.79 MAPT (0.71) MAPTKMT2AMEN1NPC1RAB9A
SCHEMBL24590486 0.77 MAPT (0.72) MAPTKMT2AMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT2, GPR119, DGAT1 MAPT 2561/4885KMT2A 1599/4885MEN1 3117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.